Evaluating Effaclar Duo+M for treating mild to moderate acne
Evaluation of Effaclar Duo+M on Inflammatory and Non-Inflammatory Lesions in Subjects With Mild to Moderate Acne on Face and Trunk (Back and Chest)
This study is testing if a new acne treatment called Effaclar Duo+M can help people with mild to moderate acne clear up their skin over six months.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 65 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cosmetique Active International Industry-sponsored |
| Locations | 1 site (Rio de Janeiro) |
| Trial ID | NCT06463925 on ClinicalTrials.gov |
What this trial studies
This open-label, single-center study assesses the effectiveness of Effaclar Duo+M and Effaclar+M Purifying foaming gel in reducing acne lesions on the face and trunk over a period of six months. Participants with mild to moderate acne will be monitored for changes in total acne lesion count, pigmented lesions, and scars. The study adheres to ethical guidelines and employs statistical methods to analyze the data collected during the trial.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with mild to moderate acne on their face and trunk, with skin types ranging from phototype I to VI.
Not a fit: Patients with other skin conditions in the treatment area or those currently undergoing conflicting topical or systemic treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide an effective topical treatment option for individuals suffering from mild to moderate acne.
How similar studies have performed: Previous studies have shown positive outcomes with similar topical treatments for acne, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * phototype I to VI * mild to moderate acne on the face and trunk Exclusion Criteria: * cutaneous pathology on the studied zone other than acne * topical or systemic treatment during the previous weeks liable to interfere with the assessment of the acceptability and efficacy of the studied products
Where this trial is running
Rio de Janeiro
- CIDP Brasil — Rio de Janeiro, Brazil (Recruiting)
Study contacts
- Principal investigator: Renato Moura — Centre International de Développement Pharmaceutique (CIDP)
- Study coordinator: Alessandro Nascimento
- Email: a.nascimento@cidp-cro.com
- Phone: +55 21 98726-2046
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.